Naproxennatrium Banner (Naproxen Sodium)

Naproxen sodium blocks the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for converting arachidonic acid into prostaglandins. By lowering prostaglandin levels, it reduces inflammation, diminishes pain signals, and helps control fever.

The appropriate dose of Naproxennatrium Banner is determined by the prescribing healthcare professional based on the patient’s condition, age, weight, and overall health. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of naproxen sodium in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Naproxen sodium has a relatively long half‑life compared with ibuprofen or diclofenac, allowing less frequent dosing. Its efficacy in pain and inflammation is comparable, but individual tolerability, gastrointestinal risk, and cardiovascular profile may differ, so clinicians choose based on patient‑specific factors.

Naproxennatrium Banner should be stored at ambient temperature, below 25 °C, in its original packaging. The container should be kept away from moisture, direct sunlight and excessive heat to maintain product stability.

The product is taken orally, usually with a full glass of water. It may be taken with food or milk to lessen stomach irritation, but patients should follow the specific instructions provided by their prescriber.

Serious risks include gastrointestinal bleeding or ulceration, severe renal impairment, cardiovascular events such as heart attack or stroke, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be monitored for these events, especially if they have pre‑existing risk factors.

Individuals with a known hypersensitivity to naproxen, other NSAIDs, or any component of the formulation should avoid the product. It is also contraindicated in patients with active gastrointestinal bleeding, severe heart failure, or advanced renal disease unless specifically directed by a physician.